The estimated Net Worth of James Healy is at least $72.3 Million dollars as of 25 May 2023. James Healy owns over 3,534 units of Natera Inc stock worth over $4,799,898 and over the last 10 years he sold NTRA stock worth over $67,031,577. In addition, he makes $481,794 as Independent Director at Natera Inc.
James has made over 31 trades of the Natera Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 644,000 units of NTRA stock worth $37,835,000 on 13 December 2023.
The largest trade he's ever made was buying 700,000 units of Natera Inc stock on 2 July 2019 worth over $11,200,000. On average, James trades about 76,785 units every 42 days since 2014. As of 25 May 2023 he still owns at least 38,762 units of Natera Inc stock.
You can see the complete history of James Healy stock trades at the bottom of the page.
Dr. James I. Healy M.D., Ph.D. serves as Independent Director of the Company. Dr. Healy has been a general partner at Sofinnova Investments, Inc. (formerly Sofinnova Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer Healthcare Pharmaceuticals (OTCMKTS: BAYRY) (as successor to Miles Laboratories), a research based pharmaceutical company, and ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently on the board of directors of Ascendis Pharma A/S (Nasdaq: ASND), a clinical-stage biopharmaceutical company; Coherus BioSciences, Inc. (Nasdaq: CHRS), a biologics platform company; Karuna Therapeutics Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company; Nucana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company; ObsEva SA (Nasdaq: OBSV), a clinical-stage biopharmaceutical company; Y-mAbs (Nasdaq: YMAB), an oncology biologics development company; and two private companies. Dr. Healy has previously served on a number of public company boards of directors, including Amarin Corporation plc (Nasdaq: AMRN), a commercial-stage biopharmaceutical company; Anthera Pharmaceuticals, Inc. (OTCMKTS: ANTH), a biopharmaceutical company; Auris Medical Holding AG (Nasdaq: EARS), a specialty pharmaceuticals company; Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company; and Iterum Therapeutics PLC (Nasdaq: ITRM), a clinical-stage pharmaceutical company; and several private companies. Dr. Healy holds a Bachelor of Arts in Molecular Biology and in Scandinavian Studies from the University of California at Berkeley, and an M.D. and Ph.D. in Immunology from Stanford University School of Medicine. Our board of directors believes that Dr. Healy is qualified to serve as a director due to his significant medical background, extensive experience investing and working in the life science industry, and his extensive service on the boards of directors of other public and private life sciences compan
As the Independent Director of Natera Inc, the total compensation of James Healy at Natera Inc is $481,794. There are 14 executives at Natera Inc getting paid more, with Steven Chapman having the highest compensation of $6,200,910.
James Healy is 55, he's been the Independent Director of Natera Inc since 2014. There are 6 older and 11 younger executives at Natera Inc. The oldest executive at Natera Inc is Herman Rosenman, 72, who is the Independent Director.
James's mailing address filed with the SEC is C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753.
Over the last 14 years, insiders at Natera Inc have traded over $290,138,276 worth of Natera Inc stock and bought 2,046,493 units worth $38,018,986 . The most active insiders traders include Matthew Rabinowitz, James Healy und Roelof Botha. On average, Natera Inc executives and independent directors trade stock every 9 days with the average trade being worth of $3,415,231. The most recent stock trade was executed by Steven Leonard Chapman on 15 August 2024, trading 5,583 units of NTRA stock currently worth $663,875.
natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
Natera Inc executives and other stock owners filed with the SEC include: